Buprenorphine alone and in combination with naloxone in non-dependent humans.
This study evaluated the effects of concurrent naloxone on the opioid agonist effects of buprenorphine, a mixed agonist-antagonist marketed as an analgesic and under development as a treatment for drug abuse. In a residential laboratory seven non-physically-dependent opioid abuser volunteers received intramuscular buprenorphine (0.4 mg or 0.8 mg/70 kg) alone and in combination with naloxone (0.4 mg or 0.8 mg/70 kg) versus placebo. Buprenorphine produced dose-related opioid agonist effects on physiological and subjective measures. Concurrent naloxone attenuated the opioid agonist effects of buprenorphine. Thus, a combination product of buprenorphine and naloxone may have lower abuse liability than buprenorphine alone.
Weinhold
L L
LL
Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Preston
K L
KL
Farre
M
M
Liebson
I A
IA
Bigelow
G E
GE
D000328:Adult; D002047:Buprenorphine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D004341:Drug Evaluation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000494:pharmacology*; D019966:Substance-Related Disorders; D013647:Task Performance and Analysis
D004338:Drug Combinations; D009270:Naloxone; D002047:Buprenorphine